Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

prothya biosolutions netherlands b.v. - human serum albumin - innrennslislyf, lausn - 200 g/l

Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

prothya biosolutions netherlands b.v. - human albumin - innrennslislyf, lausn - 40 g/l

Islande - islandais - LYFJASTOFNUN (Icelandic Medicines Agency)

prothya biosolutions netherlands b.v. - factor ii human; factor vii human; factor ix human; factor x human - stungulyfsstofn og leysir, lausn - 500 a.e.

Union européenne - islandais - EMA (European Medicines Agency)

taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - antineoplastic lyfjum - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

Union européenne - islandais - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - sýkingar af völdum sýklalyfja - bóluefni - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Union européenne - islandais - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - kyrningahvítblæði, mergbólga - Æxlishemjandi lyf - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.

Union européenne - islandais - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; spondylitis, ankylosing; crohn disease; colitis, ulcerative; hidradenitis suppurativa; psoriasis; arthritis, rheumatoid - Ónæmisbælandi lyf - vinsamlegast skoðaðu kafla 4. 1 af samantekt á eiginleikum vöru í upplýsingaskjalinu.

Union européenne - islandais - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - adalimumab - hidradenitis suppurativa; arthritis, psoriatic; psoriasis; crohn disease; arthritis, juvenile rheumatoid; uveitis; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - Ónæmisbælandi lyf - vinsamlegast skoðaðu kafla 4. 1 af samantekt á eiginleikum vöru í upplýsingaskjalinu.

Union européenne - islandais - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozin - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - lyf notuð við sykursýki - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. of the annex. heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure.  chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease.

Union européenne - islandais - EMA (European Medicines Agency)

eli lilly nederland b.v. - dúlaglútíð - sykursýki, tegund 2 - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. fyrir rannsókn árangri með tilliti til sturtu, áhrif á blóðsykursstjórnun og hjarta viðburði, og íbúa rannsakað, sjáðu kafla 4. 4, 4. 5 og 5.